PhRMA Says Integrilin FCA Suit Stifles Free Speech Rights
The Pharmaceutical Research and Manufacturers of America on Friday urged a California federal court to dismiss a whistleblower's False Claims Act suit accusing two drugmakers of misbranding heart medication Integrilin and...To view the full article, register now.
Already a subscriber? Click here to view full article